Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral esketamine pilot study for depression or demoralization in advanced cancer palliative care
NL-OMON49647Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by University Medical Center Groningen. Primary endpoint: Feasibility of a larger efficacy trial. Started Jan 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON49647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49647.